Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report report published on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of Evoke Pharma stock opened at $2.79 on Friday. The firm’s 50 day moving average is $4.25 and its 200 day moving average is $4.63. The firm has a market capitalization of $4.17 million, a PE ratio of -0.25 and a beta of 0.12. Evoke Pharma has a 1 year low of $2.50 and a 1 year high of $12.32.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The firm had revenue of $3.31 million for the quarter, compared to the consensus estimate of $3.08 million.

Institutional Trading of Evoke Pharma

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC boosted its stake in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.